[Amphastar] February 2026 Monthly Revenue NT$2.238 Billion (YoY +131.5%)
Amphastar (1795) announced astonishing financial results, with February 2026 monthly revenue soaring to NT$2.238 billion, representing a significant year-on-year increase of 131.5%. As a leading generic drug manufacturer in the Asia-Pacific region, this strong performance is likely driven by the success of high-value products such as addiction treatment drugs in overseas markets.
📋 Article Processing Timeline
- 📰 Published: February 1, 2026 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (1559h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:18 (16h 18m after Collected)
Company Code: 1795
Company Name: Amphastar Pharmaceuticals
Industry: Biotechnology and Medical Industry
Data Month/Year: 2026-02
Current Month Revenue: 2,238,173 Thousand NTD (NT$2.238 Billion)
Year-on-year Change: +131.5%
Company Name: Amphastar Pharmaceuticals
Industry: Biotechnology and Medical Industry
Data Month/Year: 2026-02
Current Month Revenue: 2,238,173 Thousand NTD (NT$2.238 Billion)
Year-on-year Change: +131.5%